Dan M Berney

List of Publications by Year
in descending order

207 papers	9,539 citations	41627 51 h-index	53065 89 g-index
212 all docs	212 docs citations	212 times ranked	12975 citing authors

#	Article	IF	Citations
1	Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. European Journal of Cancer, 2022, 164, 105-113.	1.3	12
2	Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 271, 138-144.	0.5	6
3	Looking forward for â€™ Histopathology â€˜. Histopathology, 2022, 80, 253-254.	1.6	0
4	ETS transcription factor ELF3 (ESEâ€1) is a cell cycle regulator in benign and malignant prostate. FEBS Open Bio, 2022, 12, 1365-1387.	1.0	0
5	An introduction to the <scp>WHO</scp> 5th edition 2022 classification of testicular tumours. Histopathology, 2022, 81, 459-466.	1.6	32
6	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology, 2022, 81, 426-438.	1.6	39
7	<scp>WHO</scp> Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology, 2022, 81, 447-458.	1.6	10
8	The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part A: Renal, Penile, and Testicular Tumours. European Urology, 2022, 82, 458-468.	0.9	212
9	Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery. European Urology Focus, 2021, 7, 835-842.	1.6	5
10	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 50-61.	1.1	18
11	Pathologists can get it right the first time. Journal of Clinical Pathology, 2021, 74, 271-272.	1.0	10
12	Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system?. Modern Pathology, 2021, 34, 834-841.	2.9	8
13	The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). British Journal of Cancer, 2021, 124, 368-374.	2.9	10
14	2019 Gleason grading recommendations from ISUP and GUPS: broadly concordant but with significant differences. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 813-815.	1.4	5
15	The Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis. Cancers, 2021, 13, 345.	1.7	6
16	CTNNB1-Mutant Aldosterone-Producing Adenomas With Somatic Mutations of GNA11/GNAQ Have Distinct Phenotype and Genotype. Journal of the Endocrine Society, 2021, 5, A65-A66.	0.1	0
17	ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. American Journal of Surgical Pathology, 2021, 45, 1118-1126.	2.1	36
18	Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Annals of Diagnostic Pathology, 2021, 52, 151733.	0.6	9

#	Article	IF	Citations
19	Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. Nature Genetics, 2021, 53, 1360-1372.	9.4	37
20	Headâ€toâ€head review: a new format for the journal. Histopathology, 2021, 78, 230-230.	1.6	0
21	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
22	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinicâ€“Pathologic Correlations. Cells, 2021, 10, 3165.	1.8	9
23	Prospective molecular and morphological assessment of testicular prepubertal-type teratomas in postpubertal men. Modern Pathology, 2020, 33, 713-721.	2.9	13
24	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232.	5.1	364
25	Doseâ€dense chemotherapy for untreated poorâ€prognosis and relapsed germâ€cell tumours: an 18â€year experience with GAMEC chemotherapy. BJU International, 2020, 125, 843-852.	1.3	4
26	Ovarian germ cell tumour classification: views from the testis. Histopathology, 2020, 76, 25-36.	1.6	21
27	Borderline Gleason scores: communication is the key. Journal of Clinical Pathology, 2020, 73, 616-617.	1.0	1
28	Overexpression of Placental Growth Factor in Stromal Cells from Benign Prostatic Hyperplasia: Another Piece in the Puzzle?. European Urology Open Science, 2020, 21, 29-32.	0.2	0
29	Personalized histopathology reporting for personalized medicine: a plea for improved communication. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 323-325.	1.4	1
30	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 777-786.	1.4	20
31	Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 2020, 52, 507-514.	0.3	20
32	Macroscopy under the microscope: a critical reappraisal of grossing techniques. Histopathology, 2020, 76, 930-933.	1.6	6
33	Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. Journal of Urology, 2020, 203, 73-82.	0.2	30
34	OR34-07 Prospective Multicentre Study Comparing 11C-metomidate PET CT with Adrenal Vein Sampling (AVS) in the Detection of Unilateral Aldosterone-Producing Adenomas (APAs). Journal of the Endocrine Society, 2020, 4, .	0.1	0
35	Reply by Authors. Journal of Urology, 2020, 203, 81-82.	0.2	0
36	Pathological risk factors for metastatic disease at presentation in testicular seminomas with focus on the recent pT changes in AJCC TNM eighth edition. Human Pathology, 2019, 94, 16-22.	1.1	10

#	Article	IF	Citations
37	Phospholipase D2 in prostate cancer: protein expression changes with Gleason score. British Journal of Cancer, 2019, 121, 1016-1026.	2.9	5
38	Somatic Transformation in Metastatic Testicular Germ Cell Tumours â€“ A Different Disease Entity. Anticancer Research, 2019, 39, 4911-4916.	0.5	9
39	Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a webâ€based survey by the European Network of Uropathology. Histopathology, 2019, 74, 844-852.	1.6	7
40	The molecular pathogenesis of penile carcinomaâ€”current developments and understanding. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 397-405.	1.4	25
41	The percentage of highâ€grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death. Histopathology, 2019, 75, 589-597.	1.6	11
42	Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene, 2019, 38, 5381-5395.	2.6	59
43	Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Modern Pathology, 2019, 32, 1303-1309.	2.9	25
44	Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases. Annals of Diagnostic Pathology, 2019, 39, 63-68.	0.6	12
45	Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry. American Journal of Surgical Pathology, 2019, 43, 361-368.	2.1	13
46	Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study. BMJ Open, 2019, 9, e033713.	0.8	6
47	From This Month's Histopathology. Histopathology, 2019, 75, 785-786.	1.6	0
48	Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. Histopathology, 2019, 74, 171-183.	1.6	13
49	Annual review issue. Histopathology, 2019, 74, 3-3.	1.6	0
50	Evolution not revolution. Histopathology, 2019, 74, 217-218.	1.6	0
51	Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer. Endocrine Connections, 2019, 8, 571-578.	0.8	3
52	Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP.. Journal of Clinical Oncology, 2019, 37, e16560-e16560.	0.8	0
53	The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumors. American Journal of Cancer Research, 2019, 9, 855-871.	1.4	1
54	Improving Anatomic Pathology in Sub-Saharan Africa to Support Cancer Care. American Journal of Clinical Pathology, 2018, 149, 310-315.	0.4	5

#	Article	IF	Citations
55	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	9.4	182
56	Intraoperative Consultation and Macroscopic Handling. American Journal of Surgical Pathology, 2018, 42, e33-e43.	2.1	16
57	Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 599-604.	1.4	4
58	Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology, 2018, 73, 8-18.	1.6	36
59	Contemporary prostate biopsy reporting: insights from a survey of cliniciansâ€™ use of pathology data. Journal of Clinical Pathology, 2018, 71, 874-878.	1.0	21
60	SWI/SNF protein expression status in fumarate hydrataseâ€“deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients. Human Pathology, 2018, 77, 139-146.	1.1	18
61	Incidentally detected testicular lesions <10 mm in diameter: can orchidectomy be avoided?. BJU International, 2018, 121, 575-582.	1.3	48
62	The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expertâ€driven recommendations. Histopathology, 2018, 72, 893-904.	1.6	52
63	Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation. British Journal of Cancer, 2018, 118, 189-199.	2.9	39
64	Testicular cancer. Nature Reviews Disease Primers, 2018, 4, 29.	18.1	299
65	Metastatic spermatocytic tumour with hybrid genetics: breaking the rules in germ cell tumours. Pathology, 2018, 50, 562-565.	0.3	9
66	The Prognostic Value of PIK3CA Copy Number Gain in Penile Cancer. Urology, 2018, , .	0.5	5
67	Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively. Oncotarget, 2018, 9, 20555-20562.	0.8	14
68	Gleason score assignment is the sole responsibility of the pathologist. Histopathology, 2018, 73, 5-7.	1.6	12
69	PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer. PLoS ONE, 2018, 13, e0198905.	1.1	5
70	Analysis of the PI3K-AKT-mTOR pathway in penile cancer: evaluation of a therapeutically targetable pathway. Oncotarget, 2018, 9, 16074-16086.	0.8	16
71	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. ELife, 2018, 7, .	2.8	217
72	<scp>UICC</scp> drops the ball in the 8th edition <scp>TNM</scp> staging of urological cancers. Histopathology, 2017, 71, 5-11.	1.6	37

#	Article	IF	Citations
73	Reporting and Staging of Testicular Germ Cell Tumors. American Journal of Surgical Pathology, 2017, 41, e22-e32.	2.1	66
74	SDHA mutated paragangliomas may be at high risk of metastasis. Endocrine-Related Cancer, 2017, 24, L43-L49.	1.6	19
75	Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Annals of Diagnostic Pathology, 2017, 29, 17-22.	0.6	29
76	The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis. Clinical Cancer Research, 2017, 23, 5112-5122.	3.2	50
77	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2â€“Positive Metastatic Bladder Cancer. Journal of Clinical Oncology, 2017, 35, 48-55.	0.8	165
78	Postchemotherapy changes in testicular germ cell tumours: biology and morphology. Histopathology, 2017, 70, 26-39.	1.6	9
79	Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC). American Journal of Surgical Pathology, 2017, 41, 1299-1308.	2.1	107
80	Acromegaly and Cushing's syndrome caused by a neuroendocrine tumor arising within a sacrococcygeal teratoma. Clinical Case Reports (discontinued), 2017, 5, 1768-1771.	0.2	3
81	Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer. Scientific Reports, 2017, 7, 5124.	1.6	17
82	The World Health Organization 2016 classification of testicular nonâ€germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 513-521.	1.6	143
83	The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology, 2017, 70, 335-346.	1.6	165
84	Reply to â€˜Comment on â€œValidation of a contemporary prostate cancer grading system using prostate cancer death as outcomeâ€â€™. British Journal of Cancer, 2017, 116, e4-e4.	2.9	0
85	Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. Clinical Endocrinology, 2017, 86, 286-296.	1.2	34
86	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. PLoS Genetics, 2017, 13, e1007001.	1.5	34
87	Creation and pilot testing of cases for case-based learning: A pedagogical approach for pathology cancer diagnosis. African Journal of Laboratory Medicine, 2017, 6, 637.	0.2	6
88	Liver metastases in germ cell tumors.. Journal of Clinical Oncology, 2017, 35, 403-403.	0.8	1
89	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. American Journal of Surgical Pathology, 2016, 40, 60-71.	2.1	139
90	Germ cell neoplasia in situ (<scp>GCNIS</scp>): evolution of the current nomenclature for testicular preâ€invasive germ cell malignancy. Histopathology, 2016, 69, 7-10.	1.6	123

#	Article	IF	Citations
91	Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. Clinical Cancer Research, 2016, 22, 1265-1273.	3.2	23
92	Giant intra-abdominal mature cystic teratoma (dermoid cyst) in an adult man, with male genitourinary tissue including prostatic and penile elements. Human Pathology, 2016, 54, 1-7.	1.1	3
93	Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. British Journal of Cancer, 2016, 114, 1078-1083.	2.9	105
94	Fumarate Hydrataseâ€“deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. American Journal of Surgical Pathology, 2016, 40, 865-875.	2.1	182
95	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	1.6	82
96	The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with highâ€dose chemotherapy as consolidation: a nonâ€cisplatinâ€based induction approach. BJU International, 2016, 117, 418-423.	1.3	13
97	Telomerase Activity and Telomere Length in Human Benign Prostatic Hyperplasia Stem-like Cells and Their Progeny Implies the Existence of Distinct Basal and Luminal Cell Lineages. European Urology, 2016, 69, 551-554.	0.9	15
98	DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes. PLoS ONE, 2016, 11, e0146740.	1.1	19
99	NKAIN2 functions as a novel tumor suppressor in prostate cancer. Oncotarget, 2016, 7, 63793-63803.	0.8	7
100	A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors. Oncotarget, 2016, 7, 71833-71840.	0.8	19
101	Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. PLoS ONE, 2015, 10, e0138032.	1.1	174
102	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology, 2015, 67, 313-324.	1.6	41
103	Active surveillance for prostate cancer: the role of the pathologist. Pathology, 2015, 47, 1-3.	0.3	8
104	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics, 2015, 47, 367-372.	9.4	380
105	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. Clinical Cancer Research, 2015, 21, 4212-4223.	3.2	33
106	Tumors of the Testis. Surgical Pathology Clinics, 2015, 8, 687-716.	0.7	39
107	A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients.. Journal of Clinical Oncology, 2015, 33, 4505-4505.	0.8	12
108	Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.. Journal of Clinical Oncology, 2015, 33, e16040-e16040.	0.8	1

#	Article	IF	Citations
109	Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.. Journal of Clinical Oncology, 2015, 33, 54-54.	0.8	0
110	High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 15127-36.	1.3	6
111	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	1.4	41
112	DNA methylation gene-based models indicating independent poor outcome in prostate cancer. BMC Cancer, 2014, 14, 655.	1.1	22
113	Transcription-Mediated Chimeric RNAs in Prostate Cancer: Time to Revisit Old Hypothesis?. OMICS A Journal of Integrative Biology, 2014, 18, 615-624.	1.0	28
114	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405.	1.2	117
115	DNA methylation of PITX2 predicts poor survival in men with prostate cancer. Biomarkers in Medicine, 2014, 8, 1143-1150.	0.6	23
116	The reasons behind variation in <scp>G</scp>leason grading of prostatic biopsies: areas of agreement and misconception among 266 <scp>E</scp>uropean pathologists. Histopathology, 2014, 64, 405-411.	1.6	59
117	Brain metastases associated with germ cell tumors may be treated with chemotherapy alone. Cancer, 2014, 120, 1639-1646.	2.0	14
118	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology, 2014, 65, 216-227.	1.6	40
119	Best Practices Recommendations in the Application of Immunohistochemistry in Testicular Tumors. American Journal of Surgical Pathology, 2014, 38, e50-e59.	2.1	97
120	Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology. American Journal of Surgical Pathology, 2014, 38, 1017-1022.	2.1	155
121	Identification of ZDHHC14 as a novel human tumour suppressor gene. Journal of Pathology, 2014, 232, 566-577.	2.1	44
122	Diagnosing unilateral primary aldosteronism â€“ comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clinical Endocrinology, 2014, 81, 25-30.	1.2	37
123	Endonasal endoscopic transsphenoidal pituitary surgery: early experience and outcome in paediatric <scp>C</scp>ushing's disease. Clinical Endocrinology, 2014, 80, 270-276.	1.2	38
124	Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 583-587.	1.4	20
125	The Molecular Biology of Renal Cancer: Another Piece of the Puzzle. European Urology, 2014, 66, 85-86.	0.9	4
126	Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factorâ€“Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. European Urology, 2014, 66, 956-963.	0.9	38

#	Article	IF	Citations
127	The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer.. Journal of Clinical Oncology, 2014, 32, 408-408.	0.8	2
128	Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort.. Journal of Clinical Oncology, 2014, 32, 5059-5059.	0.8	0
129	Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer. American Journal of Cancer Research, 2014, 4, 886-96.	1.4	6
130	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. Clinical Cancer Research, 2013, 19, 6924-6934.	3.2	62
131	Standardization of Gleason grading among 337 European pathologists. Histopathology, 2013, 62, 247-256.	1.6	148
132	Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology, 2013, 62, 827-839.	1.6	57
133	Prostate needle biopsy processing: a survey of laboratory practice across Europe. Journal of Clinical Pathology, 2013, 66, 120-123.	1.0	26
134	Evidence Supporting the Existence of Benign Teratomas of the Postpubertal Testis. American Journal of Surgical Pathology, 2013, 37, 827-835.	2.1	70
135	A thymic carcinoid tumour causing Zollinger-Ellison and Cushingâ€™s syndromes due to ectopic ACTH and gastrin secretion. Hormones, 2013, 12, 305-308.	0.9	6
136	A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora kinase inhibitor GSK1070916A.. Journal of Clinical Oncology, 2013, 31, 2525-2525.	0.8	8
137	Update on testis tumours. Pathology, 2012, 44, 419-426.	0.3	3
138	Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 103-107.	1.4	32
139	Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology. Journal of Clinical Pathology, 2012, 65, 106-113.	1.0	37
140	The prognostic value of Ki-67 expression in penile squamous cell carcinoma. Journal of Clinical Pathology, 2012, 65, 534-537.	1.0	32
141	Dermoid Cyst of the Testis With Neural Tissue in an Adult. Urology, 2012, 79, e25-e26.	0.5	7
142	Differential Diagnosis of Adrenocorticotropic Hormone-Independent Cushing Syndrome: Role of Adrenal Venous Sampling. Endocrine Practice, 2012, 18, e153-e157.	1.1	16
143	Oncogene-induced senescence in pituitary adenomas and carcinomas. Hormones, 2012, 11, 297-307.	0.9	31
144	Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 1014-1023.	1.5	46

#	Article	IF	Citations
145	A prospective evaluation of postural stimulation testing, computed tomography and adrenal vein sampling in the differential diagnosis of primary aldosteronism. Clinical Endocrinology, 2012, 76, 182-188.	1.2	41
146	Staging of prostate cancer. Histopathology, 2012, 60, 87-117.	1.6	114
147	Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis. Histopathology, 2012, 60, 1-3.	1.6	4
148	A Contemporary Update on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy Specimens. European Urology, 2012, 62, 20-39.	0.9	85
149	Utility of whole slide imaging and virtual microscopy in prostate pathology. Apmis, 2012, 120, 298-304.	0.9	45
150	Highâ€resolution genomeâ€wide copyâ€number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 579-589.	1.5	49
151	The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer.. Journal of Clinical Oncology, 2012, 30, 427-427.	0.8	5
152	The different genetic alterations between Western and Chinese prostate cancers and the underlying mechanisms.. Journal of Clinical Oncology, 2012, 30, 184-184.	0.8	0
153	Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status. American Journal of Cancer Research, 2012, 2, 736-44.	1.4	17
154	Cushing Syndrome Secondary to A Thymic Carcinoid Tumor Due to Multiple Endocrine Neoplasia Type 1. Endocrine Practice, 2011, 17, e92-e96.	1.1	26
155	Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncology, The, 2011, 12, 245-255.	5.1	668
156	Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer Using Pyrosequencing. Disease Markers, 2011, 30, 151-161.	0.6	74
157	Alternative HER/PTEN/Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas. PLoS ONE, 2011, 6, e17517.	1.1	73
158	Multiglandular Parathyroid Carcinoma: Case Report and Review of The Literature. Endocrine Practice, 2011, 17, 598-601.	1.1	0
159	THE TUMOURâ€NODEâ€METASTASIS STAGING OF PROSTATE CANCER IN TRANSURETHRAL RESECTION OF THE PROSTATE CHIPS REQUIRES REVISION. BJU International, 2011, 107, 351-352.	1.3	1
160	The retinoblastoma protein/p16^{INK4A} pathway but not p53 is disrupted by human papillomavirus in penile squamous cell carcinoma. Histopathology, 2011, 58, 433-439.	1.6	27
161	Handling and reporting of transurethral resection specimens of the bladder in Europe: a webâ€based survey by the European Network of Uropathology (ENUP). Histopathology, 2011, 58, 579-585.	1.6	31
162	The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. European Urology, 2011, 60, 448-454.	0.9	104

#	Article	IF	Citations
163	Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers. Acta OncolÃ³gica, 2011, 50, 76-84.	0.8	53
164	Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 175-182.	1.4	60
165	Evaluation of prediagnostic prostateâ€specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. International Journal of Cancer, 2011, 128, 2373-2381.	2.3	18
166	An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent. Modern Pathology, 2011, 24, 58-63.	2.9	33
167	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Modern Pathology, 2011, 24, 39-47.	2.9	127
168	Role of histopathology and molecular markers in the active surveillance of prostate cancer. Acta OncolÃ³gica, 2011, 50, 56-60.	0.8	8
169	Pathology in prostate research: Optimizing the pathological data. Acta OncolÃ³gica, 2011, 50, 49-52.	0.8	7
170	Pathology in prostate research: Optimizing tissue quality. Acta OncolÃ³gica, 2011, 50, 53-55.	0.8	3
171	A practical application of analysing weighted kappa for panels of experts and EQA schemes in pathology. Journal of Clinical Pathology, 2011, 64, 257-260.	1.0	3
172	Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. American Journal of Cancer Research, 2011, 1, 604-17.	1.4	26
173	Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Disease Markers, 2011, 30, 151-61.	0.6	52
174	Primary Carcinoid Tumors of the Testis: A Clinicopathologic Study of 29 Cases. American Journal of Surgical Pathology, 2010, 34, 519-524.	2.1	70
175	Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 547-553.	1.4	7
176	Androgen-Induced TMPRSS2:ERG Fusion in Nonmalignant Prostate Epithelial Cells. Cancer Research, 2010, 70, 9544-9548.	0.4	93
177	SOX9 Elevation in the Prostate Promotes Proliferation and Cooperates with PTEN Loss to Drive Tumor Formation. Cancer Research, 2010, 70, 979-987.	0.4	119
178	Distinct Genomic Alterations in Prostate Cancers in Chinese and Western Populations Suggest Alternative Pathways of Prostate Carcinogenesis. Cancer Research, 2010, 70, 5207-5212.	0.4	150
179	Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. European Journal of Endocrinology, 2010, 162, 971-978.	1.9	64
180	PRKC-Â Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. Genes and Cancer, 2010, 1, 444-464.	0.6	46

#	Article	IF	Citations
181	The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers. American Journal of Pathology, 2010, 176, 2607-2615.	1.9	89
182	Biomarkers for prostate cancer detection and progression: Beyond prostate-specific antigen. Drug News and Perspectives, 2010, 23, 185.	1.9	7
183	Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocrine-Related Cancer, 2009, 16, 515-525.	1.6	35
184	Nonclassic Lipoid Congenital Adrenal Hyperplasia Masquerading as Familial Glucocorticoid Deficiency. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3865-3871.	1.8	138
185	HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Modern Pathology, 2009, 22, 1160-1168.	2.9	77
186	p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU International, 2009, 104, 20-24.	1.3	39
187	The European Network of Uropathology: a novel mechanism for communication between pathologists. , 2009, 31, 90-5.		3
188	Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer, 2008, 112, 69-74.	2.0	65
189	Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. European Radiology, 2008, 18, 2885-2892.	2.3	108
190	Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian Journal of Andrology, 2008, 10, 467-473.	0.8	41
191	Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. Modern Pathology, 2008, 21, 54-59.	2.9	40
192	DNA topoisomerase I and IIÎ± expression in penile carcinomas: assessing potential tumour chemosensitivity. BJU International, 2008, 102, 1040-1044.	1.3	6
193	Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDHâ€B) gene mutation carriers. Clinical Endocrinology, 2008, 69, 587-596.	1.2	81
194	Local Progression among Men with Conservatively Treated Localized Prostate Cancer: Results from the Transatlantic Prostate Group. European Urology, 2008, 53, 347-354.	0.9	19
195	The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2390-2401.	1.8	273
196	Late recurrence of an ovarian yolk sac tumour as a carcinosarcoma. Pathology, 2007, 39, 601-603.	0.3	0
197	GAMEC â€“ a new intensive protocol for untreated poor prognosis and relapsed or refractory germ cell tumours. British Journal of Cancer, 2007, 97, 308-314.	2.9	25
198	THE CASE FOR MODIFYING THE GLEASON GRADING SYSTEM. BJU International, 2007, 100, 725-726.	1.3	13

#	Article	IF	Citations
199	Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU International, 2007, 100, 1240-1244.	1.3	39
200	The association between intratubular seminoma and invasive germ cell tumorsâ˜†. Human Pathology, 2006, 37, 458-461.	1.1	20
201	The Immunohistochemical Profile of Malignant Mesotheliomas of the Tunica Vaginalis. American Journal of Surgical Pathology, 2006, 30, 1-6.	2.1	57
202	Adult Leydig Cell Tumors of the Testis Caused by Germline Fumarate Hydratase Mutations. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3071-3075.	1.8	113
203	The Frequency and Distribution of Intratubular Trophoblast in Association With Germ Cell Tumors of the Testis. American Journal of Surgical Pathology, 2005, 29, 1300-1303.	2.1	16
204	Assessing the size and stage of testicular germ cell tumours: 1984-2003. BJU International, 2005, 96, 819-821.	1.3	28
205	Association between Large-scale Genomic Homozygosity without Chromosomal Loss and Nonseminomatous Germ Cell Tumor Development. Cancer Research, 2005, 65, 9137-9141.	0.4	14
206	Choriocarcinoma with teratoma arising from an intra-abdominal testis in patient with persistent MÃ¼llerian duct syndrome. Lancet Oncology, The, 2004, 5, 451-452.	5.1	16
207	TESTICULAR TUMOR PRESENTING AS HEMATOSPERMIA. Journal of Urology, 2001, 165, 188-188.	0.2	27